Seeking Alpha


Send Message
View as an RSS Feed
Latest  |  Highest rated
  • Treanda® plus Rituxan® followed by Zevalin® - New Standards for NHL & Indolent Lymphoma [View instapost]
    One problem is that Bexxar does a better job of advertising than Zevalin which is unfortunate. This, in my opinion, is the biggest error this company is making with this drug (and a very fixable error). In addition, according to my oncologist, the makers of Zevalin are no longer making it on demand, rather only twice a month which as a patient is a pain in the rear. I am trying to time the bone marrow crash and have now partly lost the ability to do so. Makes me think about considering Bexxar even though Bexxar (but not Zeavlin) risks your thyroid...

    From the investor side someone needs to get after this company to more aggressively market their drug. Lack of marketing is going to kill them, rather than lack of efficacy of the drug - it is very, very effective for many patients. They need to advertise studies like this, address the MD fears of long term bone marrow suppression and potential effects on a future stem cell transplant (I know some patients who have had Zevalin both before and after a stem cell transplant so there is probably some data out there, if not there needs to be and perhaps tracking the people in this study - and others like it - will provide the data). The marketing need to be both to the doctor (especially the doctors who write the standards for treatment - that would be really cost effective to target them as there are no that many - along with the major non-Hodgkin's lymphoma centers in the USA since most of us at least go to one for a second opinion so this would be cost effective as well) and to the patient (via the non-hodgkin's lymphoma yahoo group, the website that listowner keeps which is a wealth of information about this disease, and support to other patient boards with ads. *I* am the one who found out about this and brought it to my doctor's attention.

    As your first poster said, Treanda and Zevalin are not competitors - they are complementary.

    I am a patient (follicular non-Hodgkin's lymphoma) who just finished Rituxan/Treanda and am waiting for my counts to recover to do Zeaviln. I have a PhD in business.
    Apr 24 02:11 PM | Likes Like |Link to Comment
1 Comment